MicroConstants In-Licenses China-Discovered Antibody for $16 Million

MicroConstants China in-licensed global rights to novel discovered-in-China AA98 antibodies from Beijing's Institute of Biophysics, Chinese Academy of Sciences. With anti-angiogenesis and anti-metastasis mechanisms, AA98 antibodies are possible treatments for various cancers, multiple sclerosis and age-related macular degeneration. The AA98 drug candidates covered in the agreement were developed in the lab of Prof. Xiyun Yan, Director of IBP's Key Laboratory of Protein and Peptide Drugs. MicroConstants agreed to a package of more than $16 million in upfront and development milestones plus royalties on sales. The deal includes an AA98-based diagnostic. More details.... Share this with colleagues: // //